3-Oxoacyl-ACP Reductase from Schistosoma japonicum: Integrated In Silico-In Vitro Strategy for Discovering Antischistosomal Lead Compounds
Open Access
- 7 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e64984
Abstract
Schistosomiasis is a disease caused by parasitic worms and more than 200 million people are infected worldwide. The emergence of resistance to the most commonly used drug, praziquantel (PZQ), makes the development of novel drugs an urgent task. 3-oxoacyl-ACP reductase (OAR), a key enzyme involved in the fatty acid synthesis pathway, has been identified as a potential drug target against many pathogenic organisms. However, no research on Schistosoma japonicum OAR (SjOAR) has been reported. The characterization of the SjOAR protein will provide new strategies for screening antischistosomal drugs that target SjOAR. After cloning the SjOAR gene, recombinant SjOAR protein was purified and assayed for enzymatic activity. The tertiary structure of SjOAR was obtained by homology modeling and 27 inhibitor candidates were identified from 14,400 compounds through molecular docking based on the structure. All of these compounds were confirmed to be able to bind to the SjOAR protein by BIAcore analysis. Two compounds exhibited strong antischistosomal activity and inhibitory effects on the enzymatic activity of SjOAR. In contrast, these two compounds showed relatively low toxicity towards host cells. The work presented here shows the feasibility of isolation of new antischistosomal compounds using a combination of virtual screening and experimental validation. Based on this strategy, we successfully identified 2 compounds that target SjOAR with strong antischistosomal activity but relatively low cytotoxicity to host cells.Keywords
This publication has 43 references indexed in Scilit:
- Structure–Activity Relationships and Optimization of 3,5-Dichloropyridine Derivatives As Novel P2X7 Receptor AntagonistsJournal of Medicinal Chemistry, 2012
- Parasites and poverty: The case of schistosomiasisActa Tropica, 2010
- Reduced Susceptibility to Praziquantel among Naturally Occurring Kenyan Isolates of Schistosoma mansoniPLOS Neglected Tropical Diseases, 2009
- Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma mansoni Redox CascadePLOS Neglected Tropical Diseases, 2008
- Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug TargetPLOS Medicine, 2007
- Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at riskThe Lancet Infectious Diseases, 2006
- Combination Chemotherapy of Schistosomiasis in Laboratory Studies and Clinical TrialsAntimicrobial Agents and Chemotherapy, 2003
- Multiple Sequence Alignment Using ClustalW and ClustalXCurrent Protocols in Bioinformatics, 2002
- Crystal Structure of MabA from Mycobacterium tuberculosis, a Reductase involved in Long-chain Fatty Acid BiosynthesisJournal of Molecular Biology, 2002
- Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesisBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1996